I-Mab News

Patent Law Changes Pose Threat to I-Mab Adr's Drug Candidate Protection

TipRanksMay 1 14:02

I-MAB Filed 2023 Annual Report on Form 20-F

ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hig

I-Mab BiopharmaApr 30 12:00

Verastem Names John Hayslip as Chief Medical Officer

Verastem (VSTM) said late Thursday it appointed John Hayslip as chief medical officer, succeeding Louis Denis, who recently left the company. Hayslip most recently served as the chief medical officer

MT NewswiresApr 19 05:36

I-Mab Announces CMO Transition, Interim Successor Named

TipRanksApr 16 09:03

Needham: Reiterates the IMAB.US rating and adjusted from buy to buy, with a target price of $6.00.

Needham: Reiterates the IMAB.US rating and adjusted from buy to buy, with a target price of $6.00.

Zhitong FinanceApr 12 18:10

I-MAB Buy Rating Justified by Strong Leadership and Promising Pipeline

TipRanksApr 12 18:08

Needham Reiterates Buy on I-MAB, Maintains $6 Price Target

Needham analyst Gil Blum reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $6 price target.

BenzingaApr 12 18:04

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiate

I-Mab BiopharmaApr 5 12:00

I-Mab Finalizes Divestiture and Resolves Obligations

TipRanksApr 3 05:59

I-Mab Transferred I-Mab Biopharma (Shanghai) to I-Mab Biopharma (Hangzhou) for Up to $80M >IMAB

I-Mab Transferred I-Mab Biopharma (Shanghai) to I-Mab Biopharma (Hangzhou) for Up to $80M >IMAB

Dow JonesApr 3 04:02

I-Mab Closes Divestiture of Business Ops in China >IMAB

I-Mab Closes Divestiture of Business Ops in China >IMAB

Dow JonesApr 3 04:01

I-Mab Announces Major Leadership Reshuffle

TipRanksApr 1 21:57

NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Sec

BenzingaMar 18 19:52

I-Mab Is Maintained at Overweight by Piper Sandler

I-Mab Is Maintained at Overweight by Piper Sandler

Dow JonesMar 18 19:27

I-Mab Price Target Cut to $10.00/Share From $15.00 by Piper Sandler

I-Mab Price Target Cut to $10.00/Share From $15.00 by Piper Sandler

Dow JonesMar 18 19:27

Piper Sandler Maintains Overweight on I-MAB, Lowers Price Target to $10

Piper Sandler analyst Joseph Catanzaro maintains I-MAB with a Overweight and lowers the price target from $15 to $10.

Analyst UpgradesMar 18 19:16

HC Wainwright & Co. Reiterates Buy on I-MAB, Lowers Price Target to $8

HC Wainwright & Co. analyst Andrew Fein reiterates I-MAB with a Buy and lowers the price target from $18 to $8.

Analyst UpgradesMar 18 18:41

Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)

TipRanksMar 18 18:20

Needham Maintains Buy on I-MAB, Lowers Price Target to $6

Needham analyst Gil Blum maintains I-MAB (NASDAQ:IMAB) with a Buy and lowers the price target from $8 to $6.

BenzingaMar 15 21:28

I-MAB: A Strong Buy on Strategic U.S. Focus and Promising Oncology Pipeline

TipRanksMar 15 19:46